Jane Street Group LLC Takes $106,000 Position in Cingulate Inc. (NASDAQ:CING)

Jane Street Group LLC bought a new stake in shares of Cingulate Inc. (NASDAQ:CINGFree Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 21,031 shares of the company’s stock, valued at approximately $106,000.

Separately, Armistice Capital LLC acquired a new stake in shares of Cingulate during the second quarter worth $157,000. 41.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Roth Capital upgraded Cingulate to a “strong-buy” rating in a research report on Friday, January 10th. Maxim Group upgraded shares of Cingulate from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Roth Mkm began coverage on shares of Cingulate in a report on Friday, January 10th. They set a “buy” rating and a $12.00 price target on the stock.

Read Our Latest Research Report on CING

Cingulate Stock Down 0.2 %

Shares of Cingulate stock opened at $4.62 on Wednesday. Cingulate Inc. has a 12 month low of $1.80 and a 12 month high of $84.81. The business has a fifty day simple moving average of $4.40 and a 200-day simple moving average of $4.21.

Cingulate (NASDAQ:CINGGet Free Report) last released its earnings results on Thursday, November 7th. The company reported ($1.83) earnings per share for the quarter, beating the consensus estimate of ($2.22) by $0.39. As a group, equities research analysts expect that Cingulate Inc. will post -9.26 EPS for the current year.

Cingulate Company Profile

(Free Report)

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

Featured Stories

Want to see what other hedge funds are holding CING? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cingulate Inc. (NASDAQ:CINGFree Report).

Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.